Guidance
← Earnings Calls
01
02
03
04 05 06
Tone
AI
Capex
A1 A2
PFE
FY2026 Q2
Raised
Pfizer, Inc. earnings call
Buzzberg read
Company raises revenue guidance despite lower COVID revenues
Pfizer raised FY2026 revenue guidance on strong non-COVID execution while maintaining EPS guidance despite a $500M COVID revenue cut. Management highlighted pipeline progress in oncology and obesity, including new pivotal trials for its bispecific antibody. FY2026 revenue guidance raised by $0.5B to $60.5-62.5B, offset by a $1.0B cut in COVID revenue expectations.
Buzzberg read Company raises revenue guidance despite lower COVID revenues Pfizer raised FY2026 revenue guidance on strong non-COVID execution while maintaining EPS guidance despite a $500M COVID revenue cut. Management highlighted pipeline progress in oncology and obesity, including new pivotal trials for its bispecific antibody. FY2026 revenue guidance raised by $0.5B to $60.5-62.5B, offset by a $1.0B cut in COVID revenue expectations. Read full analysisCollapse analysis
Pfizer raised FY2026 revenue guidance on strong non-COVID execution while maintaining EPS guidance despite a $500M COVID revenue cut. Management highlighted pipeline progress in oncology and obesity, including new pivotal trials for its bispecific antibody. FY2026 revenue guidance raised by $0.5B to $60.5-62.5B, offset by a $1.0B cut in COVID revenue expectations.
- Non-COVID business delivered 5% operational revenue growth in Q2; acquired products grew 27% operationally.
- Initiated Phase 3 trials for its bispecific antibody, including a head-to-head vs. Dupixent powered for superiority.
- Updated Phase 1 data in 1L NSCLC shows ~82% ORR for its ADC+anti-PD-1 combo, supporting its Phase 3 program.
Revenue$15.034B+4% QoQ
EPS$0.77+3% QoQ
Gross margin72.78%Reported
Operating margin31.3%Reported
6 grounded callouts
What matters now
The highest-signal changes from the call.
Growth
Acquired product revenues grew 27% operationally, excluding one-time items
Costs
Additional $2.5 billion net cost savings expected from 2027-2029
Show 3 more callouts
Capital Allocation
Dividend to be maintained and eventually grow
Pipeline
Vera binitide shows potential for monthly obesity therapy with comparable efficacy
Pipeline
Telrecamig to be tested head-to-head against Dupixent in atopic dermatitis
Reported period
Actuals
| Metric | Reported | Change |
|---|---|---|
| Revenue | $15.034B | +4% QoQ |
| EPS | $0.77 | +3% QoQ |
| Gross margin | 72.78% | Reported |
| Operating margin | 31.3% | Reported |
| Free cash flow | $0.302B | Reported |
| Capex | $0.533B | Reported |
Forward-looking
Forward guidance
| Metric | Period | Range | Midpoint | Status |
|---|---|---|---|---|
| EPS | FY2026 | $2.80–$3.00 | $2.90 | Maintained |
| Revenue | FY2026 | $60.5B–$62.5B | $61.5B | Raised |
AI, capex & demand read
Management read
Confident
Management repeatedly highlighted strong execution, raised revenue guidance, and expressed confidence in future growth and dividend maintenance, despite acknowledging challenges like COVID revenue declines and pipeline setbacks.
Management AI read
Management views AI as a structural transformation opportunity, already seeing benefits in manufacturing cost reduction, yield expansion, commercial field force effectiveness, and marketing approaches, with ambitions to build an AI-native R&D organization.
Investment and capacity
Pfizer is expanding its manufacturing optimization program, expecting total net cost savings of approximately $3 billion through 2029, with additional savings from the next phase focused on network structure changes, product portfolio enhancement, and operational efficiency.
all 8 named companies below
Companiesreturns since call
Partners
Partners
Cécile Guégan
Pfizer acknowledges BMS's public guidance on Eliquis growth as a key driver for its own raised revenue guidance.
Evidence
“with a driver that our partner BMS has described”
Partners
Chris Boshoff
Pfizer highlights the scale of development for the in-licensed bispecific, signaling activity and progress on the asset.
Evidence
“Since in-licensing from 3SV about a year ago, we started nine trials including two Phase III studies”
Competitors
Competitors
Chris Boshoff
Pfizer's model projects its candidate as potentially superior to Novo's semaglutide in weight loss, a direct competitive claim.
Evidence
“the analysis suggests barabenotype can deliver weight loss comparable to desepatite and potentially better than semaglutide.”
Competitors
Chris Boshoff
Pfizer highlights its bispecific's Phase 2 data against Regeneron's ivonescimab, suggesting a potential competitive advantage.
Evidence
“these data compare favorably with Ivernissimab Phase III results in this population”
Competitors
Chris Boshoff
Pfizer references Merck's pembrolizumab as a benchmark for combination opportunity, emphasizing the clinical utility of the regimen.
Evidence
“These data align with the ability of the DOTIN ADCs to induce immunogenic cell death and thereby potentially synergize with anti-PD-1 agents such as pembrolizumab.”
Competitors
Chris Boshoff
Pfizer reports a Phase 1/2 trial design for its once-monthly GLP-1 and amylin combination is focused on tolerability, positioning it as a potential differentiated therapy. — A tolerable monthly combination could provide a significant convenience advantage over weekly rivals like Lilly's Zepbound.
Evidence
“it is encouraging that berubenatide achieved week 28 efficacy that was similar to tesepatite's medium dose of 10 mg in the SUMMOUND-1 study”
Supply chain
Supply chain
Chris Boshoff
Pfizer plans to start a Phase 3 trial for a bispecific antibody directly vs. Dupixent, powered for superiority, in a head-to-head setting. — A potential weekly alternative to Dupixent could challenge Sanofi's franchise in atopic dermatitis and asthma.
Evidence
“Indeed, this will be one of the first phase three trials that will be head against DUPI and powered for superiority against DUPI.”
External signals
Supply-chain alpha · 2returns since call
Pfizer plans to start a Phase 3 trial for a bispecific antibody directly vs. Dupixent, powered for superiority, in a head-to-head setting.
Pfizer reports a Phase 1/2 trial design for its once-monthly GLP-1 and amylin combination is focused on tolerability, positioning it as a potential differentiated therapy.
Methodology & coverage
Management-only analysis. All 8 validated company mentions are shown. Reported actuals and forward guidance are kept separate. Public evidence is limited to eight short attributed quotes. AI-generated analysis can be incomplete or wrong; verify important claims against the original source.